PHENOTYPIC CHARACTERIZATION AND VIROLOGIC RESPONSE IN HCV GENOTYPES 2 TO 6 (STUDY TMC435-C202)


<u>O Lenz</u>,¹ L Vijgen,¹ C Moreno,² JM Berke,¹ MD Cummings,¹ B Fevery,¹ M Peeters,¹ V Sekar,³ G De Smedt,¹ G Picchio³

¹Jannsen Infectious Disease BVBA, Turnhout, Belgium; ²Department of Gastroenterology and Hepatopancreatology, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium; ³Tibotec Inc., Titusville, NJ, USA

DRAG meeting, Amsterdam, The Netherlands

23 April 2013


Design of study C202 (Phase IIa)



Treatment-naïve patients infected with HCV GT 2, 3, 4, 5, and 6 were enrolled in Belgium, Germany, and Thailand


*Patients could start treatment with either PegIFNa-2a or PegIFNa-2b in combination with RBV D, day; FUP, follow-up; GT, genotype; PegIFN, pegylated interferon; PK, pharmacokinetics; QD, once daily; RBV, ribavirin; RNA, ribonucleic acid

Mean change in HCV RNA from baseline observed in study C202




Antiviral activity was observed with TMC435 in GT 2, 4, 5, and 6

*Data from study C201 TMC435 200mg monotherapy against HCV GT1 included for comparison. FUP, follow-up; GT, genotype; HCV, hepatitis C virus; RNA, ribonucleic acid; SE, standard error



Polymorphisms* observed at baseline



* V36 and L153 are buried and thus do not contribute directly to the protein surface


* Polymorphisms are defined as changes from reference (H77). Only polymorphisms at NS3 positions 36, 43, 54, 55, 80, 138, 155, 156, 168, and 170 are shown

Potent antiviral activity in 3/6 GT 2-infected patients

- GT 2b and 2c: change in HCV RNA from baseline at Day 3: -3.19 to -3.61 (log₁₀ IU/mL)

- GT 2, 2k, and 2i: change in HCV RNA from baseline at Day 3: -0.26 to -0.99 (log₁₀ IU/mL)


FUP, follow-up; GT, genotype; HCV, hepatitis C virus; PegIFN, pegylated interferon; RBV, ribavirin; RNA, ribonucleic acid




Potent antiviral activity in 3/6 GT 2-infected patients

- GT 2b and 2c: change in HCV RNA from baseline at Day 3: -3.19 to -3.61 (log₁₀ IU/mL)


- GT 2, 2k, and 2i: change in HCV RNA from baseline at Day 3: -0.26 to -0.99 (log₁₀ IU/mL)




No antiviral activity was observed with TMC435 in GT 3-infected patients



Potent antiviral activity with TMC435 in GT 4-infected patients with 2/8 patients achieving HCV RNA <25IU/mL at Day 8




Potent antiviral activity with TMC435 in GT 5-infected patients



Potent antiviral activity with TMC435 in GT 6-infected patients with 2/8 patients achieving HCV RNA <25IU/mL at Day 8

C202: correlation between individual change in HCV RNA from baseline to day 3 versus *in vitro* baseline susceptibility



Fold change in EC₅₀ values to TMC435 were assessed in a transient assay using a chimeric replicon with NS3prot derived from patient isolates, cloned into a GT 1b or JFH-1 backbone (filled circles) or SDM in a genotype 1b backbone (shape by SDM). *Cmin determined at steady state at Day 7.

Baseline susceptibility correlates with change in HCV RNA from baseline at Day 3

Summary

- TMC435 200 mg QD showed most potent antiviral activity in GT 4-, and 6-infected patients, followed by GT 5 and GT 2 (3/6 with response). No antiviral activity in GT 3.
- Good Correlation between HCV RNA changes from baseline and in vitro susceptibility (chimeric replicon assay and/or SDM) for GT 4 and GT6 (fully susceptible) as well as GT 3 (fully resistance).
- Correlation improved by including Cmin plasma exposure for isolates with low/intermediate level of resistance (GT2 and GT5)
- Change from baseline at Day 8 (efficacy) can be affected by emergence of resistant variants.

Acknowledgment

- The patients and their families
- The Investigators
- Colleagues from Janssen who contributed to this work